Get the app
public
ios_share
OncoPharm
chevron_right
It's All Immunotherapy Nowadays
Feb 23, 2018
17:23
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.
